Peter Verwaijen
Sales & Marketing at EGETIS THERAPEUTICS AB
Profile
Mr. Peter Verwaijen is a Global Head-Marketing & Brand Strategy at Egetis Therapeutics AB.
Mr. Verwaijen was previously employed as a Vice President-Finance by AM-Pharma BV and a Controller by Glaucus Proteomics BV.
Peter Verwaijen active positions
| Companies | Position | Start |
|---|---|---|
| EGETIS THERAPEUTICS AB | Sales & Marketing | 04/05/2022 |
Former positions of Peter Verwaijen
| Companies | Position | End |
|---|---|---|
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Director of Finance/CFO | - |
Glaucus Proteomics BV
 Glaucus Proteomics BV Miscellaneous Commercial ServicesCommercial Services Glaucus Proteomics BV develops antibody and protein array technologies to optimize drug development and disease management. The company was founded in 2000 and is headquartered in Utrecht, the Netherlands. | Comptroller/Controller/Auditor | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| EGETIS THERAPEUTICS AB | Health Technology |
| Private companies | 2 |
|---|---|
Glaucus Proteomics BV
Glaucus Proteomics BV Miscellaneous Commercial ServicesCommercial Services Glaucus Proteomics BV develops antibody and protein array technologies to optimize drug development and disease management. The company was founded in 2000 and is headquartered in Utrecht, the Netherlands. | Commercial Services |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
- Stock Market
- Insiders
- Peter Verwaijen
